Edition:
India

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

0.66USD
17 Jan 2018
Change (% chg)

$0.00 (+0.05%)
Prev Close
$0.66
Open
$0.66
Day's High
$0.66
Day's Low
$0.66
Volume
15,355
Avg. Vol
253,783
52-wk High
$1.55
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics
Wednesday, 3 Jan 2018 

Jan 2 (Reuters) - Repros Therapeutics Inc ::MMCAP INTERNATIONAL INC SPC REPORTS A 8.48 PCT PASSIVE STAKE IN AS OF DEC 12, 2017 - SEC FILING.  Full Article

Repros Says Received EMA Feedback That Negative Opinion Is Likely To Be Received In Jan 2018
Saturday, 16 Dec 2017 

Dec 15 (Reuters) - Repros Therapeutics Inc ::REPROS THERAPEUTICS INC.® RECEIVES FEEDBACK FOLLOWING AN ORAL EXPLANATION WITH THE EUROPEAN MEDICINES AGENCY.REPROS THERAPEUTICS - FOLLOWING ORAL EXPLANATION, HAS RECEIVED FEEDBACK THAT A NEGATIVE OPINION IS LIKELY TO BE RECEIVED IN JANUARY 2018 FROM CHMP.REPROS THERAPEUTICS INC - OPINION IS LIKELY TO BE RECEIVED FROM CHMP FOR CENTRALIZED MAA FOR ENCLOMIPHENE FOR TREATMENT OF SECONDARY HYPOGONADISM.  Full Article

Repros Therapeutics Announces Acquisition By Allergan
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Repros Therapeutics Inc ::REPROS THERAPEUTICS INC.® ANNOUNCES ACQUISITION BY ALLERGAN PLC.REPROS THERAPEUTICS INC - DEAL FOR $0.67 PER SHARE.REPROS THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH ALLERGAN PLC, THROUGH A SUBSIDIARY, WILL ACQUIRE REPROS.REPROS THERAPEUTICS INC - COMPANY'S BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED TRANSACTION.  Full Article

Repros Therapeutics Q3 loss per share $0.04
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Repros Therapeutics Inc -:Repros Therapeutics Inc.® reports third quarter 2017 financial results.Q3 loss per share $0.04.Repros Therapeutics Inc - ‍cash and cash equivalents of approximately $1.8 million as of September 30, 2017 as compared to $8.7 million as of December 31, 2016​.  Full Article

Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids
Tuesday, 13 Dec 2016 

Repros Therapeutics Inc : Says company anticipates a meeting will be scheduled during first half of 2017 . Repros Therapeutics Inc - objective of meeting with fda is primarily to agree on phase 3 clinical program .Repros requests meeting with FDA to discuss phase 3 requirements for proellex in the treatment of symptomatic uterine fibroids.  Full Article

Repros says groups showed improvement in Enclomiphene study
Tuesday, 16 Aug 2016 

Repros Therapeutics Inc : Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men .All groups showed statistically significant improvement in all metabolic parameters tested..  Full Article

Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million
Wednesday, 10 Aug 2016 

Repros Therapeutics Inc :Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million.  Full Article

Repros Therapeutics Inc. reported Q2 EPS ($0.18)
Tuesday, 9 Aug 2016 

Repros Therapeutics Inc : Repros Therapeutics Inc. reports second quarter 2016 financial results .Q2 loss per share $0.18.  Full Article

Repros Therapeutics reports Q1 loss per share of $0.20
Tuesday, 10 May 2016 

Repros Therapeutics Inc : Repros therapeutics inc.® reports first quarter 2016 financial results .Q1 loss per share $0.20.  Full Article

BRIEF-MMCAP International Reports An 8.48 Pct Passive Stake In Repros Therapeutics

* MMCAP INTERNATIONAL INC SPC REPORTS A 8.48 PCT PASSIVE STAKE IN AS OF DEC 12, 2017 - SEC FILING Source text : (http://bit.ly/2CtINer) Further company coverage: